RETRACTION NOTE

Open Access



Retraction Note to: Extranuclear ERa is associated with regression of T47D PKCa-overexpressing, tamoxifen-resistant breast cancer

Bethany Perez White^{1†}, Mary Ellen Molloy^{1†}, Huiping Zhao¹, Yiyun Zhang² and Debra A. Tonetti^{1*}

Retraction Note

This article [1] has been retracted by the authors after they discovered an error in the data. The authors recently performed Short Tandem Repeat (STR) analysis on all of their cell lines and discovered that the cell clone T47D:A18/PKC α is in fact MCF-7/PKC α . They have verified this using next generation sequencing of the p53 mutation that is a hallmark of T47D cells. All other cell lines reported in this article are as originally described. As a result of this error, parts of the article are inaccurate which affects the article's conclusions. The authors will be given the opportunity to resubmit their corrected data.

Author details

¹Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60611, USA. ²Current address: Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

Received: 11 July 2017 Accepted: 11 July 2017 Published online: 17 July 2017

Reference

 Perez White B, Molloy ME, Zhao H, Zhang Y, Tonetti DA. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing. Mol Cancer. 2013 May 1;12:34.

The online version of the original article can be found under doi:10.1186/1476-4598-12-34

¹Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60611, USA



^{*} Correspondence: dtonetti@uic.edu

[†]Equal contributors